The Role of Serum CEA and CA19-9 in Efficacy Evaluations and Progression-Free Survival Predictions for Patients Treated with Cetuximab Combined with FOLFOX4 or FOLFIRI as a First-Line Treatment for Advanced Colorectal Cancer

Table 1

Baseline patient characteristics for our cohort ().

Characteristics	No. of patients
Age (years)
Median	63
Range	47–72
Gender
Male	42
Female	31
ECOG score
0	40
1	29
2	4
Primary tumor
Colon	60
Rectum	13
Metastasis site
Liver	41
Lung	28
Local abdominal mass	10
Peritoneum	10
No. of metastatic sites
1	59
>1	14
Chemotherapy regimen
Cetuximab+FOLFOX	41
Cetuximab+FOLFIRI	32
Elevated markers at baseline
CEA (>5 ng/ml)	65
CA19-9 (>37 U/ml)	59